A Study of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin (BCG) Therapy

This study tests a new drug called RAG-01 — delivered directly into the bladder via a catheter — for people with high-grade non-muscle-invasive bladder cancer (NMIBC) whose cancer came back or did not respond after treatment with BCG (a standard bladder cancer immunotherapy). **You may be eligible if...** - You are 18 or older - You have been diagnosed with high-grade non-muscle-invasive bladder cancer - Your cancer did not respond to or came back after BCG treatment - Your expected survival is at least 6 months - Your blood counts and organ function (liver, kidneys) meet minimum requirements - You are able to tolerate a catheter placed into the bladder **You may NOT be eligible if...** - Your bladder cancer has invaded the muscle wall or spread outside the bladder - You have serious kidney, liver, or blood problems - You have active serious infections - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.